Using gain-of- function and loss-of-function assays, lncRNA CHROMR suppression inhibited DLBCL cell proliferation, invasion, enhanced DLBCL cell apoptosis, and sensitized DLBCL cells to rituximab treatment in vitro. The gene discussed is CHROMR; the disease is diffuse large B-cell lymphoma.